Isofol strengthens arfolitixorin program with new EU patent and advancing trials

An update from Isofol Medical AB ( (SE:ISOFOL) ) is now available.

Isofol Medical AB continued development of its lead cancer drug candidate arfolitixorin during the fourth quarter of 2025, advancing a phase Ib/II study in metastatic colorectal cancer with dose escalation up to 300 mg/m² and planning a phase II start later in 2026. The company reported a quarterly loss of kSEK 12,777 and a full-year loss of kSEK 54,168 with no revenue, but ended the year with kSEK 126,990 in cash and proposed no dividend, underlining its development-stage and cash-consuming profile.

Arfolitixorin attracted significant international attention as Isofol presented its study design at major oncology conferences ESMO in Berlin and ASCO-GI in the U.S., while also courting investors and partners at J.P. Morgan Week and Nordic investor events. The European Patent Office’s decision to grant a new product patent for arfolitixorin with protection until 2043 strengthens Isofol’s intellectual property position and supports its strategy to make arfolitixorin a cornerstone of future first-line cancer therapies, including through collaboration with Japanese partner Solasia Pharma K.K.

Management signals 2026 as a pivotal year, with expected data readouts from ongoing studies, further regulatory and partnering activities, and preparation for expansion of arfolitixorin into additional indications beyond metastatic colorectal cancer. This combination of advancing clinical development, reinforced patent protection and active investor and partner engagement could enhance Isofol’s competitive standing in oncology drug development while concentrating execution risk around the coming clinical milestones.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.61 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

More about Isofol Medical AB

Isofol Medical AB is a Swedish biopharmaceutical company focused on improving outcomes and quality of life for patients with severe cancers. Its lead drug candidate, arfolitixorin, is being developed to enhance the effect of first-line standard chemotherapy for solid tumors, with a primary focus on metastatic colorectal cancer. The company is listed on Nasdaq Stockholm and is positioning arfolitixorin as a potential replacement for leucovorin in standard treatment regimens.

Average Trading Volume: 437,753

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK169.5M

For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.